List of Excipients in Branded Drug GLUCOVANCE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	GLUCOVANCE	glyburide and metformin hydrochloride	54868-4609	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	GLUCOVANCE	glyburide and metformin hydrochloride	54868-4609	CROSCARMELLOSE SODIUM
Physicians Total Care Inc	GLUCOVANCE	glyburide and metformin hydrochloride	54868-4609	MAGNESIUM STEARATE
Physicians Total Care Inc	GLUCOVANCE	glyburide and metformin hydrochloride	54868-4609	POVIDONE

GLUCOVANCE Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

GLUCOVANCE is an immediate-release fixed-dose combination of glyburide, also called glibenclamide, and metformin hydrochloride for type 2 diabetes. Its commercial opportunity is primarily in generic substitution, regional supply, differentiated tolerability, and reformulated combination products rather than branded innovation. The core formulation challenge is combining a low-dose, poorly soluble sulfonylurea with a high-dose, highly soluble biguanide while maintaining content uniformity, dissolution, stability, tablet size, and bioequivalence.

What is GLUCOVANCE and how is it regulated?

GLUCOVANCE combines two oral antihyperglycemic agents:

Component	Pharmacologic class	Formulation role
Glyburide	Sulfonylurea	Low-dose, low-solubility active
Metformin hydrochloride	Biguanide	High-dose, water-soluble active
Dosage form	Immediate-release film-coated tablet	Fixed-dose combination
U.S. regulatory pathway	Small-molecule NDA and ANDA pathway	Generic applicants generally rely on ANDA approval

The original U.S. product was approved under NDA 021178. FDA-approved strengths included combinations containing 1.25 mg, 2.5 mg, or 5 mg of glyburide with 250 mg, 500 mg, or 1,000 mg of metformin hydrochloride, depending on the marketed presentation. The product was indicated as an adjunct to diet and exercise for adults with type 2 diabetes when combination treatment was appropriate.[1]

GLUCOVANCE is not a biologic, so biosimilar regulation does not apply. A competing manufacturer generally pursues an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference product, subject to FDA requirements for the relevant strength and dosage form.[2]

What excipients are used in GLUCOVANCE tablets?

The original GLUCOVANCE label identifies a conventional immediate-release tablet system using standard, broadly available excipients. The listed inactive ingredients include microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and a white film-coating system identified as Opadry.[1]

Excipient	Primary function	Commercial importance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Povidone	Binder	Improves granule and tablet cohesion
Croscarmellose sodium	Superdisintegrant	Accelerates tablet breakup
Magnesium stearate	Lubricant	Reduces punch and die friction
Opadry film coat	Appearance, swallowability, protection	Supports product identification and handling

The formulation is commercially attractive because it does not depend on a rare excipient, proprietary delivery platform, or complex manufacturing technology. A generic developer can use functionally equivalent excipients, provided the final product meets quality, dissolution, stability, and bioequivalence requirements.

Which excipients create the greatest formulation risk?

The principal technical risks are not related to excipient novelty. They arise from the interaction between the two active ingredients and from the high metformin load.

Metformin hydrochloride can account for most of the tablet mass. At the 5 mg/1,000 mg strength, the glyburide dose is small relative to metformin. This creates a content-uniformity risk, particularly if the two actives are blended directly without adequate segregation control or pre-blending of the low-dose glyburide.

Glyburide has low aqueous solubility. Its dissolution can be affected by particle size, wetting, granulation conditions, polymorphic form, surfactant selection, and compression force. Excessive lubrication can slow disintegration and dissolution. Excessive compression can create a hard tablet that passes mechanical testing but underperforms in dissolution.

A development program should therefore control:

• Glyburide particle-size distribution and solid-state form.
• Glyburide-to-metformin blend uniformity.
• Granule porosity and tablet tensile strength.
• Magnesium stearate concentration and mixing time.
• Disintegration and dissolution across multiple pH conditions.
• Moisture exposure during granulation, coating, and packaging.
• Tablet mass and dimensions across all strengths.

What excipient strategy is best for a generic GLUCOVANCE product?

The lowest-risk strategy is a conventional, functionally equivalent immediate-release formulation that remains close to the reference product in performance. The objective should be reliable bioequivalence and low cost, not excipient differentiation for its own sake.

Direct-compression strategy

Direct compression can reduce process steps and manufacturing cost. It is most attractive when both active pharmaceutical ingredients have suitable flow and compressibility and when glyburide can be distributed uniformly at the low dose.

A direct-compression formulation may use:

• Microcrystalline cellulose as the principal diluent.
• Croscarmellose sodium for rapid disintegration.
• Povidone at a controlled level if additional binding is needed.
• Magnesium stearate at the lowest level consistent with manufacturability.
• A standard film coat for identification and moisture protection.

The key commercial advantage is a short process with low capital requirements. The principal risk is glyburide segregation during blending, transfer, and tablet compression.

Wet-granulation strategy

Wet granulation provides greater control over blend uniformity and powder handling. It may be preferable for high-dose metformin strengths or for manufacturing sites with less robust direct-compression capability.

The process can be designed around:

1. Pre-blending glyburide with a portion of the diluent.
2. Separately preparing a metformin-rich granulation.
3. Combining the fractions under controlled shear.
4. Adding the extragranular disintegrant and lubricant after drying.
5. Compressing to a target hardness that preserves rapid dissolution.

Wet granulation has higher energy, equipment, and validation costs. It also creates additional moisture and drying controls. The process must prevent glyburide migration or uneven distribution during wetting and drying.

Spray-dried or micronized glyburide strategy

Particle engineering can improve glyburide wetting and dissolution. Micronization or spray drying may support more consistent release, but these approaches introduce additional control requirements for particle agglomeration, electrostatic behavior, inhalation exposure, and scale-up.

This strategy is most defensible where the reference-product dissolution profile is difficult to match using conventional excipients. It is less attractive as a first-line generic strategy if a standard formulation can demonstrate bioequivalence.

What formulations are protected by GLUCOVANCE-related intellectual property?

The commercially relevant protection historically centered on the fixed-dose combination, dosage strengths, formulation performance, and use of glyburide with metformin. The practical protection analysis requires separating three categories:

Protection category	Relevance to GLUCOVANCE	Current commercial effect
Composition-of-matter patents	Limited because both actives are established small molecules	Generally not the principal barrier
Fixed-dose combination or formulation patents	Potentially relevant during the original exclusivity period	Depends on patent expiration and Orange Book status
Method-of-use patents	Could cover treatment sequencing or patient populations	Usually narrower than the core combination

The original reference product is no longer protected by the type of market exclusivity associated with a newly launched chemical entity. Generic competition has been established in the U.S. market. The current barrier is therefore product-specific FDA approval, manufacturing economics, and reliable supply rather than a broad exclusionary patent position.

When does GLUCOVANCE lose exclusivity?

GLUCOVANCE’s core U.S. exclusivity period has expired. The product is an established small-molecule combination with generic competition. Any remaining patent issue would need to be assessed against the current FDA Orange Book entries for NDA 021178 and the relevant generic applications.[3]

There is no biosimilar exclusivity issue. A manufacturer does not need to develop a biosimilar for GLUCOVANCE; it develops an ANDA product containing the same active ingredients, strength, dosage form, and route of administration.

What is the Orange Book status of GLUCOVANCE?

The FDA Orange Book is the controlling source for current reference-product status, patent listings, exclusivity, therapeutic-equivalence codes, and discontinued-product designations.[3] GLUCOVANCE should be evaluated as a legacy NDA product with generic alternatives rather than as an active branded growth product.

For a potential ANDA sponsor, the main Orange Book tasks are:

• Confirm the current reference-listed drug status.
• Confirm which strengths remain eligible for ANDA referencing.
• Review all listed patents and regulatory exclusivities.
• Determine whether a Paragraph IV certification is required.
• Confirm the relevant therapeutic-equivalence code.
• Review any discontinuation designation affecting the reference product.

Are Paragraph IV challenges still relevant?

A Paragraph IV certification is relevant only if a listed patent remains in force and is listed against the reference product. For an older fixed-dose combination, the probability of a commercially important Paragraph IV barrier is materially lower than for a recently approved diabetes product.

If a listed patent is challenged, the applicant must provide notice to the patent owner and NDA holder. The patent owner may file an infringement action within the statutory period, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework.[4]

For GLUCOVANCE, the economic value of a Paragraph IV strategy would depend on:

• Whether any listed patent has meaningful remaining term.
• Whether the patent covers the specific strength or formulation.
• Whether the reference product remains commercially relevant.
• Whether several ANDA applicants are already approved or pending.
• Whether litigation costs are justified by expected market share.

What patent litigation and settlement risks affect GLUCOVANCE?

GLUCOVANCE is not generally viewed as a current high-value patent litigation target comparable with newer diabetes medicines such as semaglutide, tirzepatide, empagliflozin combinations, or long-acting insulin delivery systems.

The likely dispute areas are narrower:

• Paragraph IV challenges to any residual formulation or combination patents.
• ANDA infringement allegations concerning tablet composition.
• Manufacturing-process patents that are difficult to design around.
• Trade dress or trademark disputes involving the GLUCOVANCE name.
• Product-liability disputes related to hypoglycemia or gastrointestinal intolerance.

Settlement agreements would have value only if they provide an earlier generic launch date, limited license rights, or supply arrangements. For a mature product, an authorized-generic or co-marketing agreement may be more commercially significant than a patent settlement.

What are the main commercial opportunities for GLUCOVANCE excipients?

The most attractive opportunities are cost reduction, regional supply security, and formulation improvement that remains compatible with an ANDA strategy.

1. Excipient substitution and second-source supply

Manufacturers can qualify multiple suppliers for microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and film-coating materials. A dual-source strategy reduces exposure to:

• Excipient shortages.
• Shipping interruptions.
• Regional registration delays.
• Supplier-specific changes in particle size or bulk density.
• Unexpected extractables or elemental impurity findings.

The opportunity is strongest for contract manufacturers supplying multiple markets with common excipient grades.

2. Smaller, easier-to-swallow tablets

Metformin combinations can produce large tablets, particularly at the 1,000 mg metformin strength. Commercial differentiation may come from:

• Higher-density granulation.
• Improved compaction.
• Bilayer tablet design.
• Modified tablet geometry.
• Film-coat optimization.
• Alternative packaging that improves handling without increasing tablet size.

Any change must preserve immediate-release performance and satisfy applicable bioequivalence requirements.

3. Improved dissolution and food-effect control

A formulation that provides more consistent glyburide dissolution may reduce batch variability and support a stronger regulatory package. Potential tools include:

• Glyburide micronization.
• Wetting agents at low concentrations.
• Controlled granule porosity.
• Optimized superdisintegrant placement.
• Reduced hydrophobic lubricant exposure.
• More protective moisture-barrier packaging.

The commercial value is higher in jurisdictions where glyburide/metformin remains widely prescribed and where physicians use fixed-dose combinations to reduce pill burden.

4. Regional fixed-dose combination products

Demand remains concentrated in price-sensitive diabetes markets where metformin and sulfonylureas remain common because of their low acquisition cost. Potential markets include parts of Latin America, Asia, the Middle East, and Africa, subject to local treatment guidelines and registration requirements.

A regional strategy should assess:

• Whether glyburide or another sulfonylurea is preferred locally.
• Availability of 500 mg and 1,000 mg metformin strengths.
• Requirements for bioequivalence and dissolution.
• Local excipient monographs.
• Climate-zone stability requirements.
• Public-procurement pricing.
• Risk of substitution by metformin plus newer agents.

How does GLUCOVANCE compare with competing diabetes combinations?

Product type	Cost position	Clinical positioning	Patent and regulatory risk	Commercial outlook
Glyburide/metformin	Low	Legacy oral combination	Low to moderate	Volume-driven generic
Glipizide/metformin	Low	Alternative sulfonylurea combination	Low	Competitive generic segment
Metformin monotherapy	Very low	First-line foundation therapy	Low	Large, mature market
Metformin plus DPP-4 inhibitor	Medium to high	Lower hypoglycemia positioning	Higher	Brand and generic mix
Metformin plus SGLT2 inhibitor	Higher	Cardiorenal and glucose benefits	Moderate to high	Stronger strategic growth
Metformin plus GLP-1 therapy	High	Weight and glycemic control	High	Innovation-led market

GLUCOVANCE has a price and pill-burden advantage but faces clinical pressure from agents with lower hypoglycemia risk, weight benefits, or cardiovascular and renal outcome data. That limits the potential for premium pricing.

What generic launch scenarios exist for GLUCOVANCE?

Scenario 1: Low-cost conventional generic

A manufacturer launches standard immediate-release tablets using established excipients and competes on price, availability, and procurement contracts. This is the lowest-risk strategy.

Scenario 2: Multi-strength regional portfolio

The manufacturer offers several glyburide/metformin strengths and packages them for public-health tenders. The commercial advantage comes from portfolio breadth and supply reliability.

Scenario 3: Formulation-led differentiation

The manufacturer develops a smaller tablet, improved dissolution profile, or more robust moisture stability. This can support preferred formulary placement, but the regulatory and manufacturing burden is higher.

Scenario 4: Contract-manufacturing and licensing platform

An excipient supplier, formulation company, or contract development and manufacturing organization licenses a validated platform to local marketing authorization holders. The opportunity is strongest where local companies lack development capacity but have established distribution.

How strong is the GLUCOVANCE patent estate?

The patent estate is commercially weak relative to newer diabetes products because the active ingredients and basic combination have been used for decades, generic products are available, and the primary U.S. exclusivity period has ended. Any remaining formulation or method-of-use rights should be assessed claim by claim in the current Orange Book and relevant national patent registers.

The stronger barriers are operational:

• Demonstrating consistent glyburide content at low dose.
• Matching dissolution across strengths.
• Controlling tablet size at high metformin load.
• Maintaining stability in hot and humid climates.
• Securing reliable excipient supply.
• Competing against established generic manufacturers.

Key Takeaways

• GLUCOVANCE is an established immediate-release glyburide/metformin combination with generic competition.
• Its original excipient system is conventional: microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and a film coat.
• The main formulation risk is uniform distribution and dissolution of low-dose glyburide within a high-dose metformin tablet.
• Direct compression offers the lowest manufacturing cost; wet granulation may provide better blend control.
• The U.S. opportunity is primarily generic and procurement-driven, not branded.
• Biosimilar risk does not apply. The relevant pathway is an ANDA for a small-molecule fixed-dose combination.
• Commercial differentiation can come from smaller tablets, dissolution control, dual-source excipient supply, regional registration, and contract manufacturing.
• Patent barriers are likely weaker than manufacturing, regulatory, pricing, and clinical-substitution risks.
• Newer metformin combinations with SGLT2, DPP-4, or GLP-1 therapies create long-term competitive pressure.

FAQs About GLUCOVANCE Excipient and Commercial Strategy

Can a generic GLUCOVANCE product use different excipients?

Yes. A generic product can use different inactive ingredients if they are suitable for the dosage form, comply with FDA requirements, and support pharmaceutical equivalence, dissolution, stability, and bioequivalence.

Is a modified-release GLUCOVANCE tablet commercially attractive?

Potentially, but it would not be a straightforward generic substitution for the immediate-release product. A modified-release product would require a distinct regulatory and clinical development strategy, with greater formulation and bioequivalence risk.

Which GLUCOVANCE strength is most difficult to formulate?

The 5 mg glyburide/1,000 mg metformin hydrochloride strength is typically the most challenging because of the high metformin mass, large tablet burden, and low glyburide-to-total-tablet ratio.

Can GLUCOVANCE be sold as an authorized generic?

An authorized generic would require an agreement with the NDA holder or another legally available commercialization structure. Its value depends on current reference-product ownership, manufacturing rights, market demand, and regulatory status.

What packaging is most suitable for GLUCOVANCE tablets?

High-barrier bottles or blister systems are appropriate where moisture sensitivity and climate-zone stability are material concerns. The optimal choice depends on stability data, distribution conditions, packaging cost, and local regulatory requirements.

References

1. Bristol-Myers Squibb Company. (2009). GLUCOVANCE (glyburide and metformin hydrochloride) tablets prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and generic drug patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments